drugset / Trial / NCT02292433

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

NCT02292433

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

Study B1621018 will assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Dose Levels of Pf-04937319 in Japanese Subjects with Type 2 Diabetes Mellitus As Monotherapy

Timeline

Start
2015-01
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject NERIGLIATIN Small molecule 100 mg
Subject NERIGLIATIN Small molecule 250 mg